Viatris (VTRS) Stock Forecast & Price Target

Viatris is positioned for an improving growth story because its core generics business is stabilizing after prior disruption, with developed markets returning to growth in 1H26 and a large $175B branded-drug patent-cliff opportunity through 2025-2030, of which it is targeting roughly 70% through a deliberate shift toward more complex, less price-erosive molecules. Its legacy portfolio and geographically diversified platform provide a durable earnings base, while signs of stabilization in JANZ, stronger Europe and North America trends, and operational normalization after divestitures and manufacturing issues support a rebound in revenue and EBITDA growth in 2026 and beyond. The outlook is further strengthened by a restocked innovation pipeline, including fast-acting meloxicam, selatogrel, and cenerimod, which could add higher-margin branded revenue, expand the growth runway into the late 2020s and 2030s, and support a higher-quality mix over time.

Viatris is facing a weak fundamental setup because its US generics business remains exposed to pricing and competitive pressure, and any failure of the pipeline to offset that erosion could turn the segment into a drag on growth. Its APAC base business also looks fragile, with Greater China vulnerable to volume-based procurement and JANZ pressured by structural generic price reductions, which threatens the regional CAGR assumptions supporting the model. Although complex generics and biosimilars represent roughly 40% of sales and legacy brands still supply about 60%, reliance on mature products like Lipitor, Norvasc, Lyrica, and Viagra leaves the company exposed to mix deterioration and limited organic upside.